Lenacapavir: Nigeria's Breakthrough in HIV Prevention

Lenacapavir, a long-acting injectable drug, has been introduced in Nigeria as a critical tool in the fight against HIV/AIDS. Experts assert that it can significantly reduce new infections when administered biannually to HIV-negative individuals at substantial risk.

This innovation is crucial as Nigeria aims to end HIV/AIDS as a public health threat by 2030. Despite improvements in treatment access, with 93% of people living with HIV aware of their status and 95% achieving viral suppression, approximately 48,000 new infections occur annually.

The World Health Organization recommends Lenacapavir as a pre-exposure prophylaxis (PrEP) option, representing a fresh hope in HIV prevention. The drug is set to be piloted in eight states, with 52,000 doses provided by the Global Fund.

Dr. Temitop Ilori from NACA emphasized the importance of this drug in enhancing adherence among high-risk populations, while Ms.

Tina Bonto highlighted the need for sustained efforts to close prevention gaps.